Clinical Trials

1,473 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT02738866 2026-06-05

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

60 enrolled

Breast Neoplasms

NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

103 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07604571 2026-06-05

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

194 enrolled

Advanced HR+/HER2- Breast Cancer

NCT05768139 2026-06-04

PIKALO-1

BreastGynecologicHead & Neck

880 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05870579 2026-06-04

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06756932 2026-06-04

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

120 enrolled

Breast Neoplasms

NCT07174336 2026-06-04

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07288359 2026-06-04

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04567420 2026-06-03

DARE

70 enrolled

Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07226349 2026-06-03

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

105 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT05038735 2026-06-02

EPIK-B5

210 enrolled

Breast Neoplasms

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03939897 2026-06-01

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

24 enrolled 15 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07618390 2026-06-01

A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.

160 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07619066 2026-06-01

AGATHA

25 enrolled

Phase 2/3 Enrolling by invitation

Advanced Breast Cancer

NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

15 enrolled

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT04862663 2026-05-27

CAPItello-292

895 enrolled

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

399 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05472792 2026-05-26

CAMERAN

90 enrolled

Breast Neoplasms

NCT00585507 2026-05-22

Efficacy and Safety of 500mg of Fulvestrant

40 enrolled

Breast Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

130 enrolled

Breast Neoplasms, Genetic Diseases, Inborn

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

BreastGastrointestinalGynecologicHead & Neck

205 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

1,050 enrolled

Breast Neoplasm Female

NCT07540572 2026-05-20

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

160 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07029399 2026-05-19

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

361 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07117630 2026-05-19

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

40 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07340619 2026-05-19

EPIBREAST

51 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT06428396 2026-05-18

LITESPARK-029

120 enrolled

Breast Neoplasms

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

80 enrolled

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled 14 charts

Advanced Breast Cancer

NCT06110793 2026-05-13

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

54 enrolled

Breast Neoplasms

NCT06979596 2026-05-13

OMAHA-015

250 enrolled

Tumor-Agnostic

Neoplasms

NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Phase 1/2 Active not recruiting

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT07368998 2026-05-11

optINAVO

80 enrolled

Breast Neoplasms

NCT06982521 2026-05-08

ReDiscover-2

540 enrolled

Breast Neoplasms

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

BreastGynecologicThoracic

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT05646862 2026-05-06

INAVO121

420 enrolled

Breast Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors